Full Method Validation under ICH M10

Regulatory Basis of Validation Bioanalytical method validation establishes documented evidence that a method is suitable for its intended purpose and is...

Regulatory Basis of Validation

Bioanalytical method validation establishes documented evidence that a method is suitable for its intended purpose and is mandatory for methods supporting regulatory submissions, including new drug applications, abbreviated new drug applications, and investigational new drug applications. Full validation, encompassing all validation parameters, is required for a new method or a new analyte, whereas partial validation may be appropriate for minor modifications to an already validated method, and cross-validation is required whenever study samples are analysed across two different laboratories or by two different analytical methods.

Selectivity, Sensitivity, Accuracy and Precision

Selectivity is established by analysing blank matrix from at least six individual donors to confirm the absence of interference at the retention time of the analyte and internal standard, thereby demonstrating that the method can distinguish the analyte from endogenous matrix components. The lower limit of quantification represents the lowest concentration that can be measured with acceptable accuracy and precision and, unlike the limit of detection, must simultaneously satisfy both accuracy and precision acceptance criteria. Accuracy, expressed as percentage of nominal concentration, and precision, expressed as percentage coefficient of variation, are evaluated both within a single analytical run and across multiple runs performed on different days, with regulatory acceptance criteria generally requiring accuracy within eighty-five to one hundred fifteen percent of nominal and precision not exceeding fifteen percent, with somewhat relaxed criteria of twenty percent permitted at the lower limit of quantification.

Matrix Effect, Recovery, Stability, and Carryover

Matrix effect refers to alteration of analyte ionisation efficiency caused by co-eluting endogenous components and is assessed through post-column infusion experiments and calculation of the internal standard-normalised matrix factor, which corrects for analyte-specific ion suppression or enhancement using the behaviour of the stable isotope-labelled internal standard. Extraction recovery quantifies the efficiency of the sample preparation procedure by comparing analyte response in extracted matrix against that in a post-extraction spiked equivalent. Comprehensive stability assessment is required across multiple conditions, including short-term bench-top stability, freeze-thaw stability across repeated cycles, long-term frozen storage stability, processed sample stability within the autosampler, and stock and working solution stability, each evaluated against acceptance criteria requiring accuracy within eighty-five to one hundred fifteen percent of freshly prepared reference values. Dilution integrity confirms that samples exceeding the upper limit of quantification can be reliably diluted into the validated range, while carryover assessment confirms the absence of analyte transfer between sequential injections that could compromise the accuracy of subsequently analysed low-concentration samples.

Regulatory Perspective

The complete set of bioanalytical validation parameters and their acceptance criteria are formally codified in International Council for Harmonisation guideline M10 on bioanalytical method validation, which harmonises the previously distinct expectations of the United States Food and Drug Administration and the European Medicines Agency into a single globally applicable standard.